Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Southlake, TX, June 11, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing...
-
CHARLOTTE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY), the world's largest diversified manufacturer of professional dental...
-
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people...
-
Destination reinforces the sportscar maker’s commitment to experiential brand engagement in Canada Brand celebrates the one-year anniversary of the opening of its first Canadian and tenth global...
-
La destination réaffirme l’engagement du constructeur de voitures sport envers une expérience de marque immersive au Canada Porsche souligne le premier anniversaire, le 18 juin 2026, de l’ouverture...
-
BOCA RATON, FL, June 11, 2026 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”), the first U.S. public company with a treasury strategy built around accumulating and...
-
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- via AINewsWire — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) today announces its placement in an editorial published by AINewsWire (AINW), one of 75+...
-
Kennewick, WA, June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy™ (PRnT) for the treatment of cancerous tumors, is...
-
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease VANCOUVER, Washington, June 11,...
-
Pooled Phase 1/2 data show 80% complete remission rate in pediatric R/R T-ALL/LBL patients Global TENACITY-01 study reports 86% overall response rate in adults with R/R T-ALL/LBL BOSTON, June 11,...